Diana Brainard, M.D., has more than 20 years of experience in academic medicine and the biopharmaceutical industry, has authored more than 200 publications, and brings a passion for advancing therapies for life-threatening diseases.
During more than a decade at Gilead, she played an enterprise-wide leadership role building out the Virology franchise at the company, which generated more than $20 billion in revenue in 2020. As senior vice president and head of the Virology therapeutic area, she oversaw the clinical development of novel therapeutic, preventative and curative approaches for HIV, viral hepatitis, and emerging and respiratory viruses including SARS-CoV-2. Dr. Brainard began her industry career at Merck in 2007, working first in clinical pharmacology, then as infectious disease lead in experimental medicine. She joined Gilead in 2010 where she led the clinical development of four therapies for hepatitis C, approved over four years. Subsequently, her role increased to encompass responsibility for all therapeutic approaches to viral diseases including oversight of 18 approved treatments. In 2020, she led the company-wide initiative to rapidly advance remdesivir to become the first and only antiviral to receive regulatory approval for the treatment of SARS-CoV-2, which earned her global recognition as one of the most influential people in the fight against SARS-CoV-2.
Dr. Brainard also serves as a Director on the board of AlloVir as well as the Gilead Foundation and is a member of the TriNetX strategic advisory board. She performed her internal medicine and infectious diseases fellowship training at Massachusetts General Hospital and Brigham and Women’s Hospital in Boston, Massachusetts. Following completion of her medical training, she was on faculty at Harvard Medical School where she conducted NIH-funded research on HIV immunology and T-cell trafficking. Dr. Brainard received a BA in comparative literature at Brown University and an MD at Tulane University School of Medicine.